BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
Authors:
- Aurélie Cabannes‐HamyACAurélie Cabannes‐Hamy
- Rayan KabirianRKRayan Kabirian
- Floriane JochumFJFloriane Jochum
- Kevin BihanKBKevin Bihan
- Elise DumasEDElise Dumas
- Florence CoussyFCFlorence Coussy
- Enora LaasELEnora Laas
- Philippe RousselotPRPhilippe Rousselot
- Madalina UzunovMUMadalina Uzunov
- Laurent SalomonLSLaurent Salomon
- Fabien ReyalFRFabien Reyal
Open Access
- 29 May 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (3) , 705-714
Abstract
Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to investigate pregnancy and fetal/newborn adverse outcomes resulting from exposure to BCR::ABL1‐TKIs during pregnancy. For this disproportionality analysis, we used the WHO's global VigiBase up to January 2024, and included reports involving pregnancy, antineoplastic treatment during pregnancy, and cancer. The exposure group consisted of reports mentioning BCR::ABL1‐TKIs at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal‐fetal complications in the BCR::ABL1‐TKIs group compared to other anticancer treatments. The analysis included 3,389 reports (TKI = 969; other = 2,420). In the BCR::ABL1‐TKI‐exposed group, the mean age was 28.9 years, and 724 patients (92.2%) were treated for CML. BCR::ABL1‐TKIs were mainly imatinib (n = 642, 66.3%), nilotinib (n = 218, 22.5%), and dasatinib (n = 127, 13.1%) reported without other non‐TKI anticancer agents(92.3%). Compared to other anticancer drugs, overreported outcomes with TKIs included hydrops fetalis (ROR = 13 [95%CI = 1.5–110], P = 0.009), polyhydramnios (ROR = 5 [1.3–20], P = 0.02), and threatened preterm labor (ROR = 10 [1.1–90], P = 0.03). When analyzing specific molecule effects, hydrops fetalis (ROR = 27 [5.4–130], P = 0.001) and polyhydramnios (ROR = 13 [3.3–54], P = 0.004) were overreported with dasatinib. In this large cohort of 969 individuals exposed to TKIs during pregnancy, dasatinib use was associated with most BCR::ABL1‐TKI‐specific toxicities and should be avoided during pregnancy. Fewer or no adverse events were overreported with imatinib and nilotinib.Keywords
This publication has 24 references indexed in Scilit:
- Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and NewbornsJAMA Network Open, 2024
- Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and NewbornsJAMA Network Open, 2023
- Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryoBiomedicine & Pharmacotherapy, 2021
- Uses of pharmacovigilance databases: An overviewTherapies, 2020
- Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwideJournal of Community Genetics, 2018
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsLeukemia, 2017
- The impact of dasatinib on pregnancy outcomesAmerican Journal of Hematology, 2015
- The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesLeukemia, 2015
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- Cancer associated with obstetric delivery: results of linkage with the California cancer registryAmerican Journal of Obstetrics and Gynecology, 2003